NCT03534661View on ClinicalTrials.gov

L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 27, 2017

Primary Completion Date

March 20, 2019

Study Completion Date

March 20, 2019

Conditions
Hyperlipidemias
Interventions
DRUG

Teduglutide + Normal Saline

Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion

DRUG

Teduglutide + L-NMMA

Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

DRUG

Placebo + L-NMMA

Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion

Trial Locations (1)

M5G 1L7

Tornto General Hospital, UHN, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03534661 - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release | Biotech Hunter | Biotech Hunter